ResultsIQ

ResultsIQ › Latest results › Indoco Remedies Limited

Indoco Remedies Limited Q1 FY26 earnings call summary

NSE: INDOCO · BSE: 532612

Earnings call of 24 Jul 2025, summarised by AI from the filing.

European authorities approved Goa Plant-2 for sterile supply to Europe; US FDA allowed 2 of 4 lines.

Key takeaways

  1. Change European authorities approved Goa Plant-2 for sterile supply to Europe; US FDA allowed 2 of 4 lines.
  2. Driver Semi-reg markets growth driven by brand building; emerging markets revenue ₹443 million (Q1 FY25: ₹298 million).
  3. Risk US FDA warning letter on Goa Plant-2; remediation ongoing, inspection awaited.

Original filing on BSE

Indoco Remedies Limited Q1 FY27 results

As filed: Revenue ₹468 cr (+7% year on year), EBITDA ₹41.0 cr (+141% year on year), PAT ₹65.4 cr, EBITDA margin 8.8% (+489 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹476 cr (+22% year on year), EBITDA ₹49.7 cr, PAT −₹23.7 cr, EBITDA margin 10.5% (+1,000 bps). Score 45 of 100, In line with trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Share price after the results: −9.6% in 29 days (Nifty 500: −2.9%).
  • Q3 FY26: Revenue ₹445 cr (+8% year on year), EBITDA ₹31.5 cr (+163% year on year), PAT −₹29.5 cr, EBITDA margin 7.1% (+416 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 416 bps year on year. Revenue fell 8% from last quarter. Share price after the results: −6.8% in 30 days (Nifty 500: −0.6%).
  • Q2 FY26: Revenue ₹485 cr (+12% year on year), EBITDA ₹43.0 cr (+8% year on year), PAT −₹9.0 cr, EBITDA margin 8.9% (−37 bps). Score 45 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 37 bps year on year. Share price after the results: −7.1% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹438 cr (+2% year on year), EBITDA ₹17.0 cr (−65% year on year), PAT −₹36.0 cr (−300% year on year), EBITDA margin 3.9% (−726 bps). Score 20 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 726 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −10.2% in 29 days (Nifty 500: −1.9%).
  • Q4 FY25: Revenue ₹390 cr (−13% year on year), EBITDA −₹1.0 cr (−102% year on year), PAT −₹41.0 cr (−286% year on year), EBITDA margin -0.3% (−1,000 bps). Score 13 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 5% from last quarter. Share price after the results: +9.0% in 29 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹411 cr (−10% year on year), EBITDA ₹12.0 cr (−81% year on year), PAT −₹28.0 cr (−275% year on year), EBITDA margin 2.9% (−1,000 bps). Score 8 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 5% from last quarter.
  • Q2 FY25: Revenue ₹433 cr (−10% year on year), EBITDA ₹40.0 cr (−44% year on year), PAT −₹10.0 cr (−129% year on year), EBITDA margin 9.2% (−549 bps). Score 5 of 100, Below trend. EBITDA margin fell 549 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 600% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Indoco Remedies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.